ESSA Pharma Presents Early Results from Clinical Trial Testing EPI-506 in End-stage Prostate Cancer June 8, 2017 ESSA Pharma‘s small molecule androgen receptor inhibitor, EPI-506 (ralaniten acetate), has shown a favorable safety and tolerability profile among end-stage prostate cancer patients enrolled in a Phase 1/2 trial, as well as promising preliminary efficacy in higher-dose cohorts.Read more.Source: Prostate Cancer News Today Prostate Cancer News
ESSA Pharma‘s small molecule androgen receptor inhibitor, EPI-506 (ralaniten acetate), has shown a favorable safety and tolerability profile among end-stage prostate cancer patients enrolled in a Phase 1/2 trial, as well as promising preliminary efficacy in higher-dose cohorts.Read more.Source: Prostate Cancer News Today
Complete the Survey
